RapidCell is the only method for unequivocal protein identification with almost 100% accuracy. It is based on de novo sequencing of a number of protein's fragments - peptides, using high-resolution mass spectrometry. It is capable of a reliable, nonprobabilistic identification of pathogen microorganism strain (not only species or genera) or of pathogenic cells from different tissues of an organism.
Methodology:
Step 1 – sample preparation, step 2 – derivatization, step 3 – separation and analysis (on high-resolution mass spectrometry device), step 4 – identification.
More information on link: http://rapidcell.proteinacrobat.com.
Existing solutions on the market are not fulfilling all market needs. A significant number of users need additional information that is not possible to get from any other technology. Only our method can provide this specific information.
Compared with the existing technologies, we bring the following benefits:
1) Accuracy of the method (almost 100% accuracy),
2) Speed – 3 hours from sample preparation to presentation of the results,
3) Competitive price of the method (prediction - around 6 USD per sample).
E.g. doctors will have the information that will enable them prescribing the correct medical treatment. A number of lives can be saved using our technology, patients recovery is faster and trauma minimized.
1) High-resolution mass spectrometry device is needed for the analysis,
2) up to 16 analysis per day.
1) Biotyping - accurate and fast detection of pathogens and tumor cells for use in clinical practice. With existing methodologies, around 10% of the biotyping samples (from patients) are not identified. For these patients, doctors can't recommend appropriate medical treatment.
2) Protein / peptides based pharmaceuticals identity confirmation.
E.g. quality control - answers if the biogeneric drug is identical to the original drug.
Radoslav Ostermann
